Heron Therapeutics Q1 Earnings Call Highlights
Key Points - Heron reaffirmed its full-year 2026 outlook despite a weak first quarter, with net product sales of $34.7 million and adjusted EBITDA of negative $727,000. Management said seasonal issues, winter weather, and temporary supplier-related margin pressure were the